MBX Biosciences reports positive Phase II data for once-weekly canvuparatide in hypoparathyroidism, highlighting efficacy and safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback